Last reviewed · How we verify
Training+Simvastatin+Q10
This combination therapy uses exercise training with simvastatin (a statin) and coenzyme Q10 (CoQ10) to reduce cardiovascular risk through lipid lowering and mitochondrial support.
This combination therapy uses exercise training with simvastatin (a statin) and coenzyme Q10 (CoQ10) to reduce cardiovascular risk through lipid lowering and mitochondrial support. Used for Cardiovascular risk reduction in patients with dyslipidemia or statin-treated populations.
At a glance
| Generic name | Training+Simvastatin+Q10 |
|---|---|
| Also known as | Simvastatin KRKA, SQ |
| Sponsor | University of Copenhagen |
| Drug class | Combination therapy (statin + supplement + lifestyle intervention) |
| Target | HMG-CoA reductase (simvastatin); mitochondrial electron transport chain (CoQ10) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Simvastatin inhibits HMG-CoA reductase to lower LDL cholesterol and reduce atherosclerotic cardiovascular disease risk. CoQ10 supplementation counteracts statin-induced depletion of this essential mitochondrial cofactor, potentially improving muscle function and energy metabolism. Exercise training enhances cardiovascular fitness and metabolic health synergistically with pharmacotherapy.
Approved indications
- Cardiovascular risk reduction in patients with dyslipidemia or statin-treated populations
Common side effects
- Muscle pain or myalgia (simvastatin)
- Elevated liver enzymes (simvastatin)
- Gastrointestinal upset
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Training+Simvastatin+Q10 CI brief — competitive landscape report
- Training+Simvastatin+Q10 updates RSS · CI watch RSS
- University of Copenhagen portfolio CI